Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Glucarpidase
Therapeutic Area : Pharmacology/Toxicology
Study Phase : Approved FDF
Sponsor : BTG Specialty Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Company recieved positive opinion of CHMP of Voraxaze® (glucarpidase) based on clinical data and real world experience. Voraxaze reduces toxic plasma methotrexate concentration in adults and children may quickly lower MTX levels and avoid further system...
Product Name : Voraxaze
Product Type : Enzyme
Upfront Cash : Inapplicable
November 25, 2021
Lead Product(s) : Glucarpidase
Therapeutic Area : Pharmacology/Toxicology
Highest Development Status : Approved FDF
Sponsor : BTG Specialty Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable